Delving into the Latest Updates on Tripterygium Glycosides with Synapse

Overview

Basic Info

Drug Type

Herbal medicine

Synonyms

tripterygium glycosides

Target

DUSP1 x HSP70 heat-shock proteins

Mechanism

DUSP1 inhibitors(Dual specificity protein phosphatase 1 inhibitors), HSP70 heat-shock proteins inhibitors(HSP70 heat-shock proteins inhibitors)

Therapeutic Areas

Immune System DiseasesCardiovascular DiseasesCongenital Disorders+ [6]

Active Indication

Behcet SyndromeNephrotic SyndromeRheumatoid Arthritis+ [1]

Inactive Indication

Crohn Disease

Originator Organization-

Active Organization

Beijing Hospital of the Ministry of Health

Inactive Organization

Affiliated Jinling Hospital, Medical School of Nanjing University

Drug Highest PhaseApproved

First Approval Date-

Regulation-

Login to view timeline

Tripterygium glycosides (TG) is a widely used preparation in the treatment of rheumatoid arthritis (RA), nephrotic syndrome and diabetic nephropathy. Although the clinical efficacy is definite, the side-effects on reproductive system limit its wide application. It is of great significance to take measures to alleviate its reproductive toxicity and expand its clinical use. The mechanism of TG-induced reproductive toxicity involves oxidative stress, inflammation, apoptosis, and metabolism imbalance, which lead to adverse effects on male and female reproductive organs. To mitigate these effects, detoxification strategies including combining TG with other agents have been proved to counteract its toxicity. This review will provide information for the studies of TG-induced reproductive toxicity, and also provide insights for developing novel strategies to alleviate the reproductive side effects of TG.

01 Jan 2025·International Immunopharmacology

Therapeutic effects of tripterygium glycosides on periodontitis: Exploring the role of ursolic acid and the RIPK3/NLRP3 signaling pathway

Article

Author: Gao, Ying ; Chen, Li ; Yang, Lina ; Ren, Long

BACKGROUNDPeriodontitis, a chronic inflammatory disease, poses challenges in treatment due to its complex etiology. Tripterygium glycosides (TGs), renowned for their immunosuppressive and anti-inflammatory capabilities, present a prospective therapeutic option for the management of periodontitis. This study delves into the therapeutic efficacy of TGs in periodontitis and reveals the fundamental mechanisms involved.MATERIALS AND METHODSAnimal experiments were conducted to observe the therapeutic effects of TGs. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) technology was employed to identify the optimal components. Proteomic technology was used to identify differentially expressed proteins, followed by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses. Molecular docking and experimental verification of core components and targets were also performed.RESULTSTGs markedly attenuated periodontal damage and alveolar bone resorption and significantly reduced the expression of inflammatory factors. Ursolic acid (UA) was identified as a crucial active ingredient. Among the signaling pathways, the nucleotide-binding oligomerization domain-like receptor (NLR) pathway was the most prominently enriched pathway. The binding of UA to receptor-interacting protein kinase 3 (RIPK3) was demonstrated to have therapeutic efficacy. In vitro experiments verified that UA exerts anti-inflammatory effects through the RIPK3/NLRP3 signaling pathway.CONCLUSIONThis study demonstrated that TGs effectively treat periodontitis by mitigating alveolar bone loss and suppressing inflammation. As the primary component of TGs, UA exerts therapeutic effects by inhibiting the expression of RIPK3, which in turn influences the activation of the NLRP3 inflammasome and the subsequent expression of downstream inflammatory factors. The findings of this study offer a theoretical foundation for the clinical application of TGs in the management of periodontitis.

01 Dec 2024·Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae

Clinical Features of Chinese Patients With Bullous Pemphigoid Induced by Immune Checkpoint Inhibitors.

Article

Author: Li, Jing-Hui ; Zuo, Ya-Gang ; Yang, Liu-Yi-Yi ; Wang, Yan

Objective To explore the clinical features and treatments of Chinese patients with bullous pemphigoid (BP) induced by immune checkpoint inhibitors (ICI). Methods A retrospective analysis was conducted on 18 Chinese patients with ICI-induced BP treated in the Peking Union Medical College Hospital and 14 Chinese patients with this disease reported in the literature.Furthermore,the research data of non-Chinese patients were used for comparison to outline the clinical features and treatment responses of the Chinese patients. Results A total of 32 patients (21 males and 11 females) were enrolled,and all of them presented BP induced by programmed death-1/programmed death ligand-1 inhibitors.Compared with non-Chinese patients,the Chinese patients with ICI-induced BP showed low average ages [(65.2±9.5) years vs. (69.9±10.3) years,P=0.020],increased proportion of BP induced by tislelizumab (28.1% vs. 0,P<0.001),decreased proportions of BP induced by pembrolizumab (18.8% vs. 39.4%,P=0.029) and nivolumab (3.1% vs. 52.8%,P<0.001),and decreased proportion of primary malignant melanoma (9.4% vs. 43.3%,P<0.001).The incidence of pruritus (96.9% vs. 66.1%,P<0.001) and mucosal involvement (59.4% vs. 15.7%,P<0.001) in the Chinese patients were higher than those in the non-Chinese patients.The proportions of the Chinese patients treated with tripterygium glycosides (9.4% vs. 0,P=0.008),dupilumab (18.8% vs. 0.8%,P<0.001),and topical corticosteroids (87.5% vs. 53.5%,P<0.001) were higher than those of non-Chinese patients. Conclusions The Chinese patients with ICI-induced BP tend to have a younger age and a higher probability of BP induced by tislelizumab than the non-Chinese patients.Unlike that in the non-Chinese patients,the primary tumor in the Chinese patients with ICI-induced BP is predominantly lung cancer.Pruritus is more obvious,and mucosal involvement is more common in the Chinese patients.Systemic corticosteroid therapy is the international standard treatment for ICI-induced BP,while tripterygium glycosides and dupilumab are characteristic therapies in China.

100 Deals associated with Tripterygium Glycosides

Login to view more data

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Behcet Syndrome	CN	-	-
Nephrotic Syndrome	CN	-	-
Rheumatoid Arthritis	CN	-	-

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Diabetic Nephropathies	Preclinical	-	Beijing Hospital of the Ministry of Health	01 Apr 2024
Crohn Disease	Discovery	CN	Affiliated Jinling Hospital, Medical School of Nanjing University	01 Jan 2014